{
    "clinical_study": {
        "@rank": "43792", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients\n      who have glioblastoma multiforme."
        }, 
        "brief_title": "Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme", 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Assess the therapeutic activity and toxicities of nitrocamptothecin in\n      patients with glioblastoma multiforme. II. Determine the overall response, duration of\n      response, and progression free survival of these patients after this treatment.\n\n      OUTLINE: This is a multicenter study. Patients receive nitrocamptothecin orally daily on\n      days 1-5. Treatment continues every 7 days in the absence of disease progression or\n      unacceptable toxicity. Patients are followed every 6 weeks until disease progression in the\n      absence of further treatment.\n\n      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed glioblastoma multiforme\n        Recurrent disease confirmed by CT or MRI Bidimensionally measurable disease At least one\n        lesion with the largest diameter at least 2 cm\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n        least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count\n        at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN)\n        Alkaline phosphatase and transaminases no greater than 2.5 times ULN (no greater than 5\n        times ULN in case of liver metastases) Renal: Creatinine no greater than 1.7 mg/dL\n        Cardiovascular: No history of ischemic heart disease in past 6 months Other: Not pregnant\n        or nursing Fertile patients must use effective contraception No other prior or concurrent\n        malignancies except cone biopsied carcinoma of the cervix or adequately treated basal or\n        squamous cell skin carcinoma No other unstable systemic disease No active uncontrolled\n        infection No psychological, familial, sociological, or geographical condition that would\n        preclude study\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n        since prior adjuvant chemotherapy No other prior or concurrent chemotherapy allowed\n        Endocrine therapy: Concurrent corticosteroids allowed Stable or decreasing dose for at\n        least 2 weeks Radiotherapy: No high dose radiotherapy, stereotactic radiosurgery, or\n        internal radiotherapy unless recurrence is histologically confirmed At least 3 months\n        since prior radiotherapy to the brain Surgery: No prior surgery for recurrent brain tumor\n        except biopsy At least 3 months since prior surgery for primary brain tumor Other: No\n        other concurrent anticancer therapy No other concurrent investigational therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005826", 
            "org_study_id": "EORTC-16996G", 
            "secondary_id": "EORTC-16996G"
        }, 
        "intervention": {
            "intervention_name": "rubitecan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "9-nitrocamptothecin"
        }, 
        "keyword": [
            "adult glioblastoma", 
            "adult giant cell glioblastoma", 
            "adult gliosarcoma"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-16996G"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "B-2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre de Lute Contre le Cancer,Georges-Francois Leclerc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes-Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "CRLCC Nantes - Atlantique"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35062"
                    }, 
                    "name": "Centre Eugene Marquis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "F-94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padua", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Azienda Ospedaliera di Padova"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1117 MB"
                    }, 
                    "name": "Academisch Ziekenhuis der Vrije Universiteit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland", 
                        "zip": "CH-6500"
                    }, 
                    "name": "Ospedale San Giovanni"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genolier", 
                        "country": "Switzerland", 
                        "zip": "Ch-1272"
                    }, 
                    "name": "Clinique De Genolier"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Italy", 
                "Netherlands", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "official_title": "Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a \"5 Days On-2 Days Off\" Oral Treatment in Glioblastoma Multiforme", 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Eric Raymond, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "Academisch Ziekenhuis der Vrije Universiteit": "52.37 4.895", 
        "Azienda Ospedaliera di Padova": "45.41 11.877", 
        "CRLCC Nantes - Atlantique": "47.21 -1.602", 
        "Centre Eugene Marquis": "48.113 -1.676", 
        "Centre Henri Becquerel": "49.443 1.1", 
        "Centre Jean Perrin": "45.777 3.087", 
        "Centre Leon Berard": "45.764 4.836", 
        "Centre de Lute Contre le Cancer,Georges-Francois Leclerc": "47.322 5.041", 
        "Clinique De Genolier": "46.436 6.219", 
        "Hospital Universitario 12 de Octubre": "40.417 -3.7", 
        "Institut Gustave Roussy": "48.793 2.359", 
        "Ospedale San Giovanni": "46.198 9.027", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438"
    }
}